ASX - By Stock
|
RAP |
Re:
Ann: Positive engagement with US FDA following SleepCheck Pre-Sub
|
|
Deadant
|
73 |
20K |
3 |
25/11/20 |
25/11/20 |
ASX - By Stock
|
73
|
20K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
2 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
648
|
225K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
5 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
648
|
225K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
2 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
648
|
225K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Positive engagement with US FDA following SleepCheck Pre-Sub
|
|
Deadant
|
73 |
20K |
2 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
73
|
20K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Positive engagement with US FDA following SleepCheck Pre-Sub
|
|
Deadant
|
73 |
20K |
0 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
73
|
20K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Positive engagement with US FDA following SleepCheck Pre-Sub
|
|
Deadant
|
73 |
20K |
4 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
73
|
20K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Positive engagement with US FDA following SleepCheck Pre-Sub
|
|
Deadant
|
73 |
20K |
10 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
73
|
20K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
7 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
648
|
225K
|
7
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
1 |
22/11/20 |
22/11/20 |
ASX - By Stock
|
648
|
225K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
22 |
21/11/20 |
21/11/20 |
ASX - By Stock
|
648
|
225K
|
22
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
10 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
648
|
225K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
21 |
19/11/20 |
19/11/20 |
ASX - By Stock
|
648
|
225K
|
21
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResAppDx to be integrated into WMA telehealth application
|
|
Deadant
|
31 |
9.2K |
33 |
19/11/20 |
19/11/20 |
ASX - By Stock
|
31
|
9.2K
|
33
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
1 |
18/11/20 |
18/11/20 |
ASX - By Stock
|
648
|
225K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
24 |
17/11/20 |
17/11/20 |
ASX - By Stock
|
648
|
225K
|
24
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
Deadant
|
108 |
36K |
16 |
14/11/20 |
14/11/20 |
ASX - By Stock
|
108
|
36K
|
16
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
3 |
12/11/20 |
12/11/20 |
ASX - By Stock
|
648
|
225K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
18 |
12/11/20 |
12/11/20 |
ASX - By Stock
|
648
|
225K
|
18
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Medgate to pilot ResAppDx for telehealth across Europe
|
|
Deadant
|
95 |
30K |
7 |
09/11/20 |
09/11/20 |
ASX - By Stock
|
95
|
30K
|
7
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Medgate to pilot ResAppDx for telehealth across Europe
|
|
Deadant
|
95 |
30K |
27 |
09/11/20 |
09/11/20 |
ASX - By Stock
|
95
|
30K
|
27
|
|
ASX - By Stock
|
RAP |
Re:
Competitive Threat to ResApp
|
|
Deadant
|
120 |
35K |
0 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
120
|
35K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
7 |
05/11/20 |
05/11/20 |
ASX - By Stock
|
648
|
225K
|
7
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
19 |
05/11/20 |
05/11/20 |
ASX - By Stock
|
648
|
225K
|
19
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
Deadant
|
108 |
36K |
3 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
108
|
36K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Rap revenue phase
|
|
Deadant
|
104 |
34K |
7 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
104
|
34K
|
7
|
|
ASX - By Stock
|
RAP |
Re:
Competitive Threat to ResApp
|
|
Deadant
|
120 |
35K |
1 |
31/10/20 |
31/10/20 |
ASX - By Stock
|
120
|
35K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
Deadant
|
245 |
66K |
3 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
245
|
66K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Tipping Comp - what will RAP’s Revenue be sales in Sept. Qtr
|
|
Deadant
|
119 |
33K |
2 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
119
|
33K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
Deadant
|
245 |
66K |
30 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
245
|
66K
|
30
|
|
ASX - By Stock
|
RAP |
Re:
Tipping Comp - what will RAP’s Revenue be sales in Sept. Qtr
|
|
Deadant
|
119 |
33K |
1 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
119
|
33K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Tipping Comp - what will RAP’s Revenue be sales in Sept. Qtr
|
|
Deadant
|
119 |
33K |
2 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
119
|
33K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
Deadant
|
3.3K |
2.5M |
4 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
3.3K
|
2.5M
|
4
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
Deadant
|
3.3K |
2.5M |
19 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
3.3K
|
2.5M
|
19
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResAppDx launched on select Android devices
|
|
Deadant
|
66 |
16K |
2 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
66
|
16K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResAppDx launched on select Android devices
|
|
Deadant
|
66 |
16K |
6 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
66
|
16K
|
6
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResAppDx launched on select Android devices
|
|
Deadant
|
66 |
16K |
6 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
66
|
16K
|
6
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
4 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
648
|
225K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
1 |
27/10/20 |
27/10/20 |
ASX - By Stock
|
648
|
225K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Quarterly Results and Investor Conference Call Notification
|
|
Deadant
|
25 |
7.4K |
3 |
27/10/20 |
27/10/20 |
ASX - By Stock
|
25
|
7.4K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Ann: AstraZeneca to use new ResApp software in clinical study
|
|
Deadant
|
121 |
36K |
1 |
25/10/20 |
25/10/20 |
ASX - By Stock
|
121
|
36K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Ann: AstraZeneca to use new ResApp software in clinical study
|
|
Deadant
|
121 |
36K |
4 |
24/10/20 |
24/10/20 |
ASX - By Stock
|
121
|
36K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
0 |
23/10/20 |
23/10/20 |
ASX - By Stock
|
648
|
225K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Ann: AstraZeneca to use new ResApp software in clinical study
|
|
Deadant
|
121 |
36K |
2 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
121
|
36K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: AstraZeneca to use new ResApp software in clinical study
|
|
Deadant
|
121 |
36K |
3 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
121
|
36K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Pause in Trading
|
|
Deadant
|
48 |
11K |
1 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
48
|
11K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Pause in Trading
|
|
Deadant
|
48 |
11K |
0 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
48
|
11K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Ann: AstraZeneca to use new ResApp software in clinical study
|
|
Deadant
|
121 |
36K |
5 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
121
|
36K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: AstraZeneca to use new ResApp software in clinical study
|
|
Deadant
|
121 |
36K |
7 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
121
|
36K
|
7
|
|
ASX - By Stock
|
RAP |
Re:
2020 commercialisation
|
|
Deadant
|
648 |
225K |
10 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
648
|
225K
|
10
|
|